Works matching DE "ADUCANUMAB"

Results: 139

Development of monoclonal antibody therapeutics for alzheimer's disease.

Published in:

Taiwanese Journal of Psychiatry, 2022, v. 36, n. 4, p. 148, doi. 10.4103/TPSY.TPSY_31_22

By:

Takeda, Masatoshi

Publication type:

Article

Accelerated Approval of Highly Expensive Disease-modifying Agents: Lessons Learned From the Aducanumab Approval.

Published in:

Journal of Pharmacoeconomics & Pharmaceutical Management, 2022, v. 8, n. 1, p. 1

By:

Chenchula, Santenna;
R., Padmavathi

Publication type:

Article

From 1901 to 2022, how far are we from truly understanding the pathogenesis of age-related dementia?

Published in:

GeroScience, 2022, v. 44, n. 3, p. 1879, doi. 10.1007/s11357-022-00591-7

By:

Fang, Xing;
Zhang, Jin;
Roman, Richard J.;
Fan, Fan

Publication type:

Article

The dawn of disease modification for Alzheimer's disease: Hope and peril.

Published in:: Journal of the American Geriatrics Society, 2022, v. 70, n. 6, p. 1661, doi. 10.1111/jgs.17774
Publication type:: Article

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.

Published in:

Journal of the American Geriatrics Society, 2022, v. 70, n. 6, p. 1685, doi. 10.1111/jgs.17692

By:

DiStefano, Michael J.;
Alexander, G. Caleb;
Polsky, Daniel;
Anderson, Gerard F.

Publication type:

Article

A large pragmatic trial is the right solution for testing anti‐amyloid therapies for Alzheimer's disease.

Published in:

Journal of the American Geriatrics Society, 2022, v. 70, n. 5, p. 1595, doi. 10.1111/jgs.17695

By:

Glymour, M. Maria;
Mor, Vincent

Publication type:

Article

Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia.

Published in:

Journal of the American Geriatrics Society, 2021, v. 69, n. 12, p. 3690, doi. 10.1111/jgs.17462

By:

Hunt, Lauren J.;
Harrison, Krista L.;
Covinsky, Kenneth E.

Publication type:

Article

"Real world" eligibility for aducanumab.

Published in:

2021

By:

Canevelli, Marco;
Rossi, Paolo Dionigi;
Astrone, Paolo;
Consorti, Ernesto;
Vanacore, Nicola;
Cesari, Matteo

Publication type:

Letter to the Editor

Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease.

Published in:

Annals of Neurology, 2023, v. 93, n. 5, p. 877, doi. 10.1002/ana.26643

By:

Musiek, Erik S.;
McDade, Eric;
Holtzman, David M.

Publication type:

Article

Reply to A Letter Concerning "Aducanumab: What About the Patient?".

Published in:: Annals of Neurology, 2022, v. 91, n. 5, p. 733, doi. 10.1002/ana.26344
Publication type:: Article

A Letter Concerning "Aducanumab: What about the Patient?".

Published in:: Annals of Neurology, 2022, v. 91, n. 5, p. 732, doi. 10.1002/ana.26333
Publication type:: Article

Reply to "Letter Concerning Moghavem, Henderson, and Greicius Article".

Published in:

Annals of Neurology, 2021, v. 90, n. 6, p. 1006, doi. 10.1002/ana.26255

By:

Moghavem, Nuriel;
Henderson, Victor W.;
Greicius, Michael D.

Publication type:

Article

Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1004, doi. 10.1002/ana.26254
Publication type:: Article

Reply to "Thinking beyond Aducanumab Controversy".

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1004, doi. 10.1002/ana.26253
Publication type:: Article

Thinking beyond the Aducanumab Controversy.

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1003, doi. 10.1002/ana.26252
Publication type:: Article

Aducanumab: What about the Patient?

Published in:: Annals of Neurology, 2021, v. 90, n. 3, p. 334, doi. 10.1002/ana.26181
Publication type:: Article

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Published in:

Annals of Neurology, 2021, v. 90, n. 3, p. 331, doi. 10.1002/ana.26167

By:

Moghavem, Nuriel;
Henderson, Victor W.;
Greicius, Michael D.

Publication type:

Article

Alzheimer's Disease Treatment: The Search for a Breakthrough.

Published in:

Medicina (1010660X), 2023, v. 59, n. 6, p. 1084, doi. 10.3390/medicina59061084

By:

Reiss, Allison B.;
Muhieddine, Dalia;
Jacob, Berlin;
Mesbah, Michael;
Pinkhasov, Aaron;
Gomolin, Irving H.;
Stecker, Mark M.;
Wisniewski, Thomas;
De Leon, Joshua

Publication type:

Article

Tryptamine: A privileged scaffold for the management of Alzheimer's disease.

Published in:

Drug Development Research, 2023, v. 84, n. 8, p. 1578, doi. 10.1002/ddr.22111

By:

Singh, Yash P.;
Kumar, Harish

Publication type:

Article

Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.

Published in:

2025

By:

VandeVrede, Lawren;
La Joie, Renaud;
Horiki, Sheena;
Mundada, Nidhi S.;
Koestler, Mary;
Hwang, Ji-Hye;
Ljubenkov, Peter A.;
Rojas, Julio C.;
Rabinovici, Gil D.;
Boxer, Adam L.;
Seeley, William W.

Publication type:

Correction Notice

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.

Published in:

Acta Neuropathologica, 2023, v. 146, n. 5, p. 777, doi. 10.1007/s00401-023-02631-8

By:

VandeVrede, Lawren;
La Joie, Renaud;
Horiki, Sheena;
Mundada, Nidhi S.;
Koestler, Mary;
Hwang, Ji-Hye;
Ljubenkov, Peter A.;
Rojas, Julio C.;
Rabinovici, Gil D.;
Boxer, Adam L.;
Seeley, William W.

Publication type:

Article

Alzheimer disease neuropathology in a patient previously treated with aducanumab.

Published in:

Acta Neuropathologica, 2022, v. 144, n. 1, p. 143, doi. 10.1007/s00401-022-02433-4

By:

Plowey, Edward D.;
Bussiere, Thierry;
Rajagovindan, Raj;
Sebalusky, Jennifer;
Hamann, Stefan;
von Hehn, Christian;
Castrillo-Viguera, Carmen;
Sandrock, Alfred;
Budd Haeberlein, Samantha;
van Dyck, Christopher H.;
Huttner, Anita

Publication type:

Article

Kleinová L, Cerman J, Hlávka J et al. Nové farmakologické možnosti v léčbě Alzheimerovy nemoci.

Published in:

Česká a Slovenská Neurologie a Neurochirurgie, 2023, v. 86, n. 4, p. 289

By:

Míšková, Iva

Publication type:

Article

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve.

Published in:

Biomedicines, 2024, v. 12, n. 12, p. 2918, doi. 10.3390/biomedicines12122918

By:

Niazi, Sarfaraz K.

Publication type:

Article

The Fuzzy Border between the Functional and Dysfunctional Effects of Beta-Amyloid: A Synaptocentric View of Neuron–Glia Entanglement.

Published in:

Biomedicines, 2023, v. 11, n. 2, p. 484, doi. 10.3390/biomedicines11020484

By:

Fagiani, Francesca;
Fulop, Tamas;
Govoni, Stefano;
Lanni, Cristina

Publication type:

Article

Symposium 08: Neuropsychological Considerations for Alzheimer's Disease Clinical Trials.

Published in:

2023

By:

Kiselica, Andrew;
Duff, Kevin

Publication type:

Abstract

Anti-amyloid agents for treating incipient Alzheimer's disease: a new hope?

Published in:

2022

By:

Loureiro, Julia C.;
Silva, Luiz Fernando A. L.;
Pais, Marcos V.;
Forlenza, Orestes V.

Publication type:

Editorial

New and emerging drug therapies for Alzheimer disease.

Published in:

Australian Prescriber, 2024, v. 47, n. 3, p. 75, doi. 10.18773/austprescr.2024.021

By:

Waite, Louise M.

Publication type:

Article

Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review.

Published in:

Alzheimer's Research & Therapy, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13195-023-01238-1

By:

Dickson, Samuel P.;
Hennessey, Sean;
Nicodemus Johnson, Jessie;
Knowlton, Newman;
Hendrix, Suzanne B.

Publication type:

Article

Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2024, v. 60, n. 1, p. 1, doi. 10.1186/s41983-024-00845-5

By:

Ameen, Taha Basit;
Kashif, Syeda Naveera;
Abbas, Syed Muhammad Iraj;
Babar, Kulsoom;
Ali, Syed Muhammad Sinaan;
Raheem, Abdul

Publication type:

Article

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.

Published in:

Journal of Neuroscience, 2016, v. 36, n. 50, p. 12549, doi. 10.1523/JNEUROSCI.2080-16.2016

By:

Kastanenka, Ksenia V.;
Bussiere, Thierry;
Shakerdge, Naomi;
Fang Qian;
Weinreb, Paul H.;
Rhodes, Ken;
Bacskai, Brian J.

Publication type:

Article

Should Canadian patients look forward to aducanumab for Alzheimer disease?

Published in:

2021

By:

Watt, Jennifer A.;
Marple, Roger;
Hemmelgarn, Brenda;
Straus, Sharon E.

Publication type:

journal article

Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer's disease: A case report.

Published in:

2023

By:

Restifo, Linda L;
Erickson, Robert P

Publication type:

Case Study

Immunothérapie passive dans la maladie d'Alzheimer : état des lieux et applicabilité en population gériatrique.

Published in:

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 2023, v. 21, n. 2, p. 233, doi. 10.1684/pnv.2023.1099

By:

Delrieu, Julien;
Ousset, Pierre Jean

Publication type:

Article

Actualités thérapeutiques dans la maladie d'Alzheimer : bientôt un traitement de fond ?

Published in:

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 2022, v. 20, n. 2, p. 256, doi. 10.1684/pnv.2022.1042

By:

Villain, Nicolas

Publication type:

Article

Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease.

Published in:

CNS Drugs, 2022, v. 36, n. 4, p. 365, doi. 10.1007/s40263-022-00915-3

By:

Argueta, Natalie;
Notari, Emily;
Szigeti, Kinga

Publication type:

Article

Alzheimer's trials.

Published in:

New Humanist, 2023, v. 138, n. 1, p. 15

By:

Leon, Lydia

Publication type:

Article

Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update.

Published in:

Journal of Biomedical Science, 2023, v. 30, n. 1, p. 1, doi. 10.1186/s12929-023-00976-6

By:

Huang, Li-Kai;
Kuan, Yi-Chun;
Lin, Ho-Wei;
Hu, Chaur-Jong

Publication type:

Article

From attention-deficit hyperactivity disorder to sporadic Alzheimer's disease--Wnt/mTOR pathways hypothesis.

Published in:

Frontiers in Neuroscience, 2023, v. 17, p. 1, doi. 10.3389/fnins.2023.1104985

By:

Grünblatt, Edna;
Homolak, Jan;
Perhoc, Ana Babic;
Davor, Virag;
Knezovic, Ana;
Barilar, Jelena Osmanovic;
Riederer, Peter;
Walitza, Susanne;
Tackenberg, Christian;
Salkovic-Petrisic, Melita

Publication type:

Article

Aducanumab: A look two years after its approval.

Published in:

Biomédica: Revista del Instituto Nacional de Salud, 2024, v. 44, p. 42, doi. 10.7705/biomedica.6967

By:

Torres, Astrid;
Camargo, Loida;
López, Norman

Publication type:

Article

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023.

Published in:

Molecular Neurodegeneration, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13024-023-00656-x

By:

Gandy, Sam

Publication type:

Article

Disease-modifying treatments in Alzheimer's disease.

Published in:

Journal of Neurology, 2023, v. 270, n. 4, p. 2342, doi. 10.1007/s00415-023-11602-8

By:

Edwards, Marc;
Corkill, Robin

Publication type:

Article

Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Published in:

2023

By:

Muralidharan, Kumar Kandadi;
Kowalski, Kenneth G.;
Tong, Xiao;
Haeberlein, Samantha Budd;
Rajagovindan, Rajasimhan;
Nestoro, Ivan

Publication type:

Correction Notice

Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Published in:

Journal of Pharmacokinetics & Pharmacodynamics, 2023, v. 50, n. 1, p. 45, doi. 10.1007/s10928-022-09839-3

By:

Muralidharan, Kumar Kandadi;
Kowalski, Kenneth G.;
Tong, Xiao;
Haeberlein, Samantha Budd;
Rajagovindan, Rajasimhan;
Nestorov, Ivan

Publication type:

Article

알츠하이머병의 진단과 치료: 최신 지견.

Published in:

Journal of the Korean Society of Radiology (2951-0805), 2025, v. 86, n. 1, p. 6, doi. 10.3348/jksr.2024.0146

By:

임영희;
문원진

Publication type:

Article

From Cholinesterase Inhibitors to Glutamate Receptors to Aducanumab: A Therapeutic Review of Alzheimer’s Disease.

Published in:

International Journal of High School Research, 2023, v. 5, n. 5, p. 47, doi. 10.36838/v5i5.9

By:

Karthikeyan, Eyyel

Publication type:

Article

OP105 Gaps, Challenges And Priorities For Neurodegenerative Disease Research And Health Technology Assessment.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S38, doi. 10.1017/S0266462322001465

By:

Salih, Fatima;
Bradshaw, Angela;
Killin, Lewis;
Coll, Nina;
Díaz, Carlos;
Diaz-Ponce, Ana;
Gove, Dianne;
Dawoud, Dalia

Publication type:

Article

Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 995, doi. 10.1007/s40120-023-00466-9

By:

Saposnik, Gustavo;
Sánchez-Benavidez, Gonzalo;
García-Arcelay, Elena;
Franco-Macías, Emilio;
Bensi, Catalina;
Carmelingo, Sebastián;
Allegri, Ricardo F.;
Pérez-Martínez, David A.;
Maurino, Jorge

Publication type:

Article

Topical Insights Into the Post-Approval Controversies of Aducanumab.

Published in:

Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.787303

By:

Kumar, Dhiraj;
Yadav, Dharmendra Kumar;
Hassan, Md Imtaiyaz

Publication type:

Article

Aducanumab, an investigational drug for AZ, submitted to FDA for priority review.

Published in:: Rhode Island Medical Journal, 2020, v. 103, n. 6, p. 96
Publication type:: Article